Table 4.

Summary of TRIPOD adherence of the 26 included studies

TRIPOD section	TRIPOD item	Reported		Not reported		Not applicable
		n	%a	n	%a	n	%
Title and abstract	1	0	0%	26	100%	0	0
	2	0	0%	26	100%	0	0
Background and objectives	3a	24	92%	2	8%	0	0
	3b	13	50%	13	50%	0	0
Source of data	4a	25	96%	1	4%	0	0
	4b	19	73%	7	27%	0	0
Participants	5a	18	69%	8	31%	0	0
	5b	24	92%	2	8%	0	0
	5c	0	-	0	-	26	100%
Outcome	6a	20	77%	6	23%	0	0
	6b	25	96%	1	4%	0	0
Predictors	7a	22	85%	4	15%	0	0
	7b	17	65%	9	35%	0	0
Sample size	8	7	27%	19	73%	0	0
Missing data	9	14	54%	12	46%	0	0
Statistical analysis methods	10a	26	100%	0	0%	0	0
	10b	2	8%	24	92%	0	0
	10c	1	8%	12	92%	13	50%
	10d	1	4%	25	96%	0	0
	10e	0	-	0	-	26	100%
Risk groups	11	3	60%	2	40%	21	81%
Development vs validation	12	7	54%	6	46%	13	50%
Participants	13a	7	27%	19	73%	0	0
	13b	6	23%	20	77%	0	0
	13c	2	15%	11	85%	13	50%
Model development	14a	22	85%	4	15%	0	0
	14b	0	0%	1	100%	25	96%
Model specification	15a	2	8%	24	92%	0	0
	15b	1	4%	25	96%	0	0
Model performance	16	2	8%	24	92%	0	0
Model updating	17	0	-	0	-	26	100%
Limitations	18	23	88%	3	12%	0	0
Interpretation	19a	12	92%	1	8%	13	50%
	19b	26	100%	0	0%	0	0
Implications	20	19	73%	7	27%	0	0
Supplementary information	21	3	12%	23	88%	0	0
Funding	22	10	38%	16	62%	0	0

TRIPOD Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis

^aCalculated over the applicable items only